作者
Jean-Louis Vincent, Bruno Francois, Igor Zabolotskikh, Mradul Kumar Daga, Jean-Baptiste Lascarrou, Mikhail Y Kirov, Ville Pettilä, Xavier Wittebole, Ferhat Meziani, Emmanuelle Mercier, Suzana M Lobo, Philip S Barie, Mark Crowther, Charles T Esmon, Jawed Fareed, Satoshi Gando, Kenneth J Gorelick, Marcel Levi, Jean-Paul Mira, Steven M Opal, Joseph Parrillo, James A Russell, Hidehiko Saito, Kazuhisa Tsuruta, Takumi Sakai, David Fineberg, SCARLET Trial Group
发表日期
2019/5/28
期刊
Jama
卷号
321
期号
20
页码范围
1993-2002
出版商
American Medical Association
简介
Importance
Previous research suggested that soluble human recombinant thrombomodulin may reduce mortality among patients with sepsis-associated coagulopathy.
Objective
To determine the effect of human recombinant thrombomodulin vs placebo on 28-day all-cause mortality among patients with sepsis-associated coagulopathy.
Design, Setting, and Participants
The SCARLET trial was a randomized, double-blind, placebo-controlled, multinational, multicenter phase 3 study conducted in intensive care units at 159 sites in 26 countries. All adult patients admitted to one of the participating intensive care units between October 2012 and March 2018 with sepsis-associated coagulopathy and concomitant cardiovascular and/or respiratory failure, defined as an international normalized ratio greater than 1.40 without other known etiology and a platelet count in the range of 30 to 150 × 109/L or a greater than 30 …
学术搜索中的文章
JL Vincent, B Francois, I Zabolotskikh, MK Daga… - Jama, 2019